Gelteq Limited (NASDAQ:GELS – Get Free Report) saw a large decline in short interest in July. As of July 15th, there was short interest totaling 112,420 shares, a decline of 32.9% from the June 30th total of 167,463 shares. Based on an average daily trading volume, of 41,384 shares, the days-to-cover ratio is currently 2.7 days. Currently, 1.0% of the shares of the stock are short sold.
Institutional Trading of Gelteq
An institutional investor recently bought a new stake in Gelteq stock. Susquehanna International Group LLP purchased a new stake in Gelteq Limited (NASDAQ:GELS – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,550 shares of the company’s stock, valued at approximately $57,000. Susquehanna International Group LLP owned approximately 0.44% of Gelteq as of its most recent filing with the Securities and Exchange Commission (SEC).
Analysts Set New Price Targets
Separately, Weiss Ratings cut shares of Gelteq from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, June 26th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Gelteq presently has a consensus rating of “Sell”.
Gelteq Price Performance
Shares of NASDAQ GELS opened at $0.55 on Friday. Gelteq has a twelve month low of $0.39 and a twelve month high of $2.02. The firm has a 50-day moving average of $0.65 and a two-hundred day moving average of $0.71.
Gelteq (NASDAQ:GELS – Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.12) earnings per share (EPS) for the quarter.
Gelteq Company Profile
Gelteq Inc is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc is based in NEW YORK.
Featured Stories
- Five stocks we like better than Gelteq
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
Receive News & Ratings for Gelteq Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelteq and related companies with MarketBeat.com's FREE daily email newsletter.
